Edesa Biotech Inc (EDSA)
1.96
-0.10 (-4.85%)
USD |
NASDAQ |
Aug 15, 16:00
1.98
+0.02 (+1.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 30.31M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -57.30% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 80.09 |
| Price to Book Value | 1.780 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.60% |
News
Headline
Wire
Time (ET)
MT Newswires
05/24 08:17
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/14/2023* | -- | Results | Q1 2023 | -- | -- | -- | |
| 05/13/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 02/14/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 08/13/2021 | -- | Results | Q3 2021 | -0.46 | -0.14 | -227.0% | |
| 05/14/2021 | -- | Results | Q2 2021 | -0.81 | -0.39 | -107.7% | |
| 02/16/2021 | -- | Results | Q1 2021 | -0.26 | -0.22 | -18.18% | |
| 12/07/2020 | -- | Results | Q4 2020 | -0.22 | -0.23 | 4.35% | |
| 08/12/2020 | -- | Results | Q3 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients. |
| URL | https://www.edesabiotech.com |
| Investor Relations URL | http://ir.stellarbiotechnologies.com/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 14, 2023 (est.) |
| Last Earnings Release | May. 13, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of August 15, 2022.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 17.34M |
| Net Income (TTM) | -17.39M |
| Total Assets (Quarterly) | 20.41M |
| Total Liabilities (Quarterly) | 3.383M |
| Shareholders Equity (Quarterly) | 17.02M |
| Cash from Operations (TTM) | -7.099M |
| Cash from Investing (TTM) | -0.0064M |
| Cash from Financing (TTM) | 11.87M |
Ratings
Profile
Edit
| Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side-effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients. |
| URL | https://www.edesabiotech.com |
| Investor Relations URL | http://ir.stellarbiotechnologies.com/ |
| HQ State/Province | Ontario |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Value |
| Next Earnings Release | Feb. 14, 2023 (est.) |
| Last Earnings Release | May. 13, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| EDSA Tweets |